Low molecular weight fucoidan ameliorates the inflammation and glomerular filtration function of diabetic nephropathy

Xu, Yingjie; Zhang, Quanbin; Luo, Di; Wang, Jing; Duan, Delin

doi:10.1007/s10811-016-0942-0

Cited by 21 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fucose is the main monosaccharide component of LMWF (highest content), followed by galactose. The relative proportion of fucose and sulfate groups was shown to be near 1 : 1, which was consistent with previous studies conducted on Laminaria japonica polysaccharides [ 37 ]. This proportion enhances the medicinal efficiency of LMWF, and it shows that the basic structure of fucoidan was not destroyed by free radical degradation.…”

Section: Discussionsupporting

confidence: 91%

Low Molecular Weight Fucoidan Inhibits Pulmonary Fibrosis In Vivo and In Vitro via Antioxidant Activity

Dong

Xue

Liu

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

In this study, sulfated polysaccharides extracted from Laminaria japonica were degraded by free radicals to obtain low molecular weight fucoidan (LMWF). The in vivo and in vitro effects of LMWF on bleomycin-treated pulmonary fibrosis mice and TGF-treated A549 cells, respectively, were evaluated, and the role of antioxidant activity was assessed. H&E, Masson’s trichrome, and Sirius red staining results showed that bleomycin induced obvious pathological changes and collagen deposition in the lung tissue of mice. However, LMWF effectively inhibited collagen deposition, and based on immunohistochemistry analyses, LMWF can also inhibit the expression of fibrosis markers. At the same time, LMWF could regulate related antioxidant factors in the lung tissue of pulmonary fibrosis mice and reduce the pressure of oxidative stress. Moreover, LMWF could improve the morphology of cells induced with TGF, which confirmed that LMWF could inhibit fibrosis via antioxidant activity modulation.

show abstract

Section: Discussionsupporting

confidence: 91%

Low Molecular Weight Fucoidan Inhibits Pulmonary Fibrosis In Vivo and In Vitro via Antioxidant Activity

Dong

Xue

Liu

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Fucoidan isolated from Saccharina japonica diminished the toxic effects of diabetes and/or aflatoxin B1 on the liver and kidneys via reducing the blood glucose levels and serum levels of IL-1β, IL-6, and TNF-α [ 9 ]. Xu et al [ 56 ] performed a similar research, however, they reported decreased kidney levels of IL-6 and no change in the TNF-α levels after treatment with LMWF from the same brown alga. A combination of LMW fucoidan from Sargassum hemiphyllum and fucoxanthin reduced the levels of TNF-α and IL-6 in diabetic mice [ 57 ].…”

Section: Anti-inflammatory Activity Of Fucoidan: Evidence From In mentioning

confidence: 95%

Immunomodulatory and Anti-Inflammatory Effects of Fucoidan: A Review

et al. 2020

View full text Add to dashboard Cite

Inflammation is the initial response of the immune system to potentially harmful stimuli (e.g., injury, stress, and infections). The process involves activation of macrophages and neutrophils, which produce mediators, such as nitric oxide (NO), prostaglandin E2 (PGE2), pro-inflammatory and anti-inflammatory cytokines. The pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α) are considered as biomarkers of inflammation. Even though it occurs as a physiological defense mechanism, its involvement in the pathogenesis of various diseases is reported. Rheumatoid arthritis, inflammatory bowel disease, Alzheimer’s disease, and cardiovascular diseases are only a part of the diseases, in which pathogenesis the chronic inflammation is involved. Fucoidans are complex polysaccharides from brown seaweeds and some marine invertebrates, composed mainly of L-fucose and sulfate ester groups and minor amounts of neutral monosaccharides and uronic acids. Algae-derived fucoidans are studied intensively during the last years regarding their multiple biological activities and possible therapeutic potential. However, the source, species, molecular weight, composition, and structure of the polysaccharides, as well as the route of administration of fucoidans, could be crucial for their effects. Fucoidan is reported to act on different stages of the inflammatory process: (i) blocking of lymphocyte adhesion and invasion, (ii) inhibition of multiple enzymes, and (iii) induction of apoptosis. In this review, we focused on the immunemodulating and anti-inflammatory effects of fucoidans derived from macroalgae and the models used for their evaluation. Additional insights on the molecular structure of the compound are included.

show abstract

“…On the seventh week, STZ was injected into DKD, FP, and LMWF rats for induction, whereas the Sham rats were administered with saline solution. Starting on the eighth week, the FP and LMWF groups were gavage fed with LMWF (200 mg/kg; dosage based on previous research [ 15 , 16 ] and fosinopril (8 mg/kg/day) for 13 weeks). The Sham and DKD groups, in contrast, were given saline solution by gastric administration.…”

Section: Methodsmentioning

confidence: 99%

Low Molecular Weight Fucoidan Can Inhibit the Fibrosis of Diabetic Kidneys by Regulating the Kidney Lipid Metabolism

Wang

Sun

Shao

et al. 2021

Journal of Diabetes Research

View full text Add to dashboard Cite

In this study, a diabetic kidney disease model was established by placing the test rats on a high-sugar/high-fat diet combined with streptozotocin induction. Histopathological examination (H&E, Masson, and PASM stain) showed pathological changes in the diabetic rat kidneys, in addition to fibrotic symptoms and collagen deposition. Immunohistochemistry and western blot analyses indicated that the diabetic condition significantly increased the expressions of fibrotic markers including collagen, α-SMA, and fibronectin. The levels of cholesterol, triglyceride, and low-density lipoprotein were also increased in diabetic kidney disease (DKD) rat blood, while the level of high-density lipoprotein was decreased. The results of Oil red O staining experiments indicated that the kidneys of diabetic rats exhibited appreciable fat deposition, with high contents of triglyceride and cholesterol. To inhibit fibrosis and reduce fat deposition, low molecular weight fucoidan (LMWF) may be used. Based on PCR and western blot analyses, LMWF can regulate the expression levels of important lipid metabolism regulators, thereby impeding the development of kidney fibrosis. Through the vitro model, it also be indicated that LMWF could inhibit fibrosis process through regulating lipid metabolism which induced by palmitic acid.

show abstract

Low molecular weight fucoidan ameliorates the inflammation and glomerular filtration function of diabetic nephropathy

Cited by 21 publications

References 55 publications

Low Molecular Weight Fucoidan Inhibits Pulmonary Fibrosis In Vivo and In Vitro via Antioxidant Activity

Low Molecular Weight Fucoidan Inhibits Pulmonary Fibrosis In Vivo and In Vitro via Antioxidant Activity

Immunomodulatory and Anti-Inflammatory Effects of Fucoidan: A Review

Low Molecular Weight Fucoidan Can Inhibit the Fibrosis of Diabetic Kidneys by Regulating the Kidney Lipid Metabolism

Contact Info

Product

Resources

About